FP
Flagship Pioneering Portfolio holdings
AUM
$268M
This Quarter Return
+2.05%
1 Year Return
-54.4%
3 Year Return
-51.2%
5 Year Return
+66.7%
10 Year Return
–
AUM
$1.33B
AUM Growth
+$1.33B
(-3.8%)
Cap. Flow
-$47.4M
Cap. Flow
% of AUM
-3.58%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
9
New
–
Increased
1
Reduced
1
Closed
2
Top Buys
| 1 |
SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
|
$2.34M |
Top Sells
| 1 |
EVLO
Evelo Biosciences, Inc. Common Stock
EVLO
|
$31.1M |
| 2 |
AXLA
Axcella Health Inc. Common Stock
AXLA
|
$12.2M |
| 3 |
Denali Therapeutics
DNLI
|
$6.44M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Moderna
MRNA
$9.37B
| $961M | 72.53% |
9,666,038
| – | – |
|
2
Sana Biotechnology
SANA
$777M
| $102M | 7.7% |
25,001,856
| – | – |
|
|
OMGA
3
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
| $88M | 6.64% |
29,225,579
| – | – |
|
4
Foghorn Therapeutics
FHTX
$286M
| $81.7M | 6.17% |
12,674,120
| – | – |
|
|
5
Denali Therapeutics
DNLI
$2.23B
| $49.8M | 3.76% |
2,319,968
-300,000
| -11% | -$6.44M |
|
6
Seres Therapeutics
MCRB
$166M
| $32.4M | 2.45% |
23,117,045
| – | – |
|
|
SYRS
7
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $10.1M | 0.76% |
1,293,848
+300,000
| +30% | +$2.34M |
|
|
AXLA
8
DELISTED
Axcella Health Inc. Common Stock
AXLA
| – | – |
-1,170,059
| Closed | -$12.2M |
|
|
EVLO
9
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
| – | – |
-7,932,624
| Closed | -$31.1M |
|